Sign up for ICER's Weekly View Newsletter

 

Weekly View


June 18, 2026

From the desk of Priya Ranade

Good morning, everyone.

We’re in your inbox a day early due to the federal Juneteenth holiday tomorrow. We hope everyone has a relaxing and safe long weekend.



But before you head out, be sure to register for ICER’s June 25th public meeting on Covid-19 vaccines. During the public meeting, an independent appraisal committee will review the findings of the ICER Evidence Report, hear further testimony from stakeholders, and deliberate on the clinical effectiveness, benefits beyond health, and long-term value for money.

Let's see what happened this week...

 

ICER in the News

 

Covid vaccine still pays off, report says

Politico


ICER: Updated COVID-19 Vaccines Offer Greatest Benefit for Older, Higher-Risk Patients

Inside Health Policy

ICER released a revised Evidence Report on Covid-19 vaccines last week. The report included four vaccines: Comirnaty® (Pfizer, BioNTech), Spikevax® (Moderna), mNexspike® (Moderna), and Nuvaxovid® (Sanofi).

 

A brief excerpt from Politico’s coverage:

 

“A prominent nonprofit that evaluates the clinical effectiveness and the value of medicines released an updated analysis Thursday that found Covid-19 vaccines to be cost-effective interventions for the coming season for all subpopulations of the U.S. at current prices. The analysis, by the Boston-based Institute for Clinical and Economic Review, said that while declining rates of severe Covid infection ‘necessarily create some uncertainties,’ the benefits of Covid vaccination are greatest for pregnant women, children ages 6 months to 1 year and seniors 65 and older.”

 
Pharmaceutical News

MUST READS


Medicare weight-loss drug coverage could overwhelm doctors

Axios


Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end

STAT

According to Axios, next month's launch of a Medicare temporary program providing weight-loss drugs for $50 a month is expected to unleash pent-up demand for Wegovy, Zepbound, and other blockbuster treatments — and create new bottlenecks at doctors' offices.

 

Additionally, STAT reported that the program may be difficult to end (CMS expects to discontinue the program in December 2027). Initially, Medicare had hoped to push private Medicare insurers to voluntarily cover the drugs through a three-year program called BALANCE, which would have begun after a short transitional period. But insurers balked, so the federal government is extending the transitional coverage program, called Bridge, until the end of next year. The problem is, the cost of the Bridge program falls entirely on taxpayers, not on health insurers. And the benefit — obesity drugs for $50 a month — will be difficult, if not impossible, to take away from older adults.

They’re Uninsured After Obamacare Became Too Costly. And They’re Far From Alone.

KFF Health News

Millions of Americans are expected to drop their Affordable Care Act insurance coverage after Congress allowed enhanced tax credits that helped pay for insurance plans to expire at the end of 2025. Established by the Biden administration’s American Rescue Plan Act during the Covid pandemic, the expanded subsidies reduced monthly premiums for many families and prompted a tidal wave of new sign-ups, doubling ACA enrollment to about 24 million.


The Centers for Medicare & Medicaid Services is expected to soon release complete data on how many people are no longer covered under the ACA, but an early analysis from KFF, citing Wakely Consulting Group research, showed enrollment could drop from over 22 million at the end of 2025 to as low as 16.5 million in 2026. 

CMS Targets Combo Drug Workaround Used To Dodge Medicare Drug Price Negotiation

Pink Sheet

CMS wants to prevent manufacturers from using subcutaneous reformulations to delay Medicare drug price negotiations. The proposal could affect Keytruda, Opdivo, Tecentriq and Ocrevus by grouping their newer subcutaneous versions with older IV products.

47% of US adults say corporate health insurers ‘primary drivers’ of rising health costs

Fierce Healthcare

As healthcare costs continue to spike in the U.S., a new survey from the Coalition to Strengthen America’s Healthcare found that nearly half of Americans (47%) view corporate health insurers as the primary driver behind affordability issues.


The federal government and drug companies followed closely behind, at 36% and 34% respectively. Hospitals and health systems were selected by 20% of respondents; pharmacy benefit managers (PBMs) were selected by 17% and doctors and medical providers were selected by 10% of respondents.

FDA approves Colorado’s plan to import cheaper drugs from Canada

STAT

The Food and Drug Administration said Monday that it will allow Colorado to import certain prescription drugs from Canada in an effort to bring prices down for residents, making it the second U.S. state to be granted such authorization. 


For more than a quarter of a century, Americans have sought drugs from Canada for relief from the ever-rising costs of medicines, sometimes taking widely publicized bus trips across the border. It wasn’t until 2020, though, that the first Trump administration officially endorsed the practice, when it published a regulation allowing states and Indian tribes to propose import plans. 

OTHER HEADLINES

 

Join ICER!

 

Want to work for a fast-paced, mission-driven organization? Look no further! ICER is looking to expand our team:



 

Key Upcoming Dates

 
  • 7/27: Parkinson's Disease -- Draft Evidence Report
  • 7/28: Covid-19 -- Final Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email